ProMIS director buys 4,000 company shares

ProMIS Neurosciences Inc. director Williams Eugene purchased a total of 4,000 Common Shares in open-market transactions over three days.

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. director Williams Eugene purchased a total of 4,000 Common Shares in open-market transactions over three days. He bought 1,000 shares at $22.53, 1,000 shares at $21.89, and 2,000 shares at $24.00. Following these purchases, he owns 10,397 Common Shares directly.

Insider Trade Summary

Net Buyer: 4,000 shares

Net Buy 3 txns

Insider Williams Eugene

Role Director

Bought 4,000 shs ($92K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	2,000	$24.00	$48K
Purchase	Common Shares	1,000	$21.89	$22K
Purchase	Common Shares	1,000	$22.53	$23K

Holdings After Transaction: Common Shares — 10,397 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ProMIS Neurosciences (PMN) insider Williams Eugene do in this Form 4?

Williams Eugene, a director of ProMIS Neurosciences, bought 4,000 Common Shares in open-market transactions. These purchases occurred over three days and increased his directly held stake in the company to 10,397 Common Shares according to the reported ownership details.

How many ProMIS Neurosciences (PMN) shares did the director purchase?

The director purchased a total of 4,000 Common Shares. The filing shows three separate open-market purchases: 1,000 shares at $22.53, 1,000 shares at $21.89, and 2,000 shares at $24.00, all classified as direct ownership transactions.

At what prices did Williams Eugene buy ProMIS Neurosciences (PMN) shares?

He bought shares at three different prices: $22.53 per share, $21.89 per share, and $24.00 per share. Each price corresponds to a separate open-market purchase of Common Shares reported in the Form 4 filing for this director.

How many ProMIS Neurosciences (PMN) shares does the director own after these trades?

After the reported purchases, the director directly owns 10,397 Common Shares. The Form 4 specifies the total shares beneficially owned following each transaction, with the final reported balance reaching 10,397 shares of the company’s common equity.

Were the ProMIS Neurosciences (PMN) insider trades classified as buys or sells?

All reported transactions were classified as buys. The Form 4 lists three non-derivative transactions coded as open-market purchases, with no sales or dispositions reported in this filing, resulting in a net increase in the director’s share ownership.

What type of security did Williams Eugene trade in ProMIS Neurosciences (PMN)?

He traded the company’s Common Shares. Each transaction in the Form 4 is identified as involving Common Shares as a non-derivative security, acquired through open-market purchases and held under direct ownership following completion of the trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 06:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Eugene

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/02/2026		P		1,000	A	$22.53	7,397	D
Common Shares	03/03/2026		P		1,000	A	$21.89	8,397	D
Common Shares	03/04/2026		P		2,000	A	$24	10,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Max A. Milbury, Attorney in Fact for Eugene Williams	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.